Neutrophil/Lymphocyte and Platelet/Lymphocyte Ratios are Not Different among Breast Cancer Subtypes

Area of Science:

• Oncology
• Inflammation markers
• Breast cancer subtypes

Background:

• Breast cancer is a complex disease with diverse subtypes exhibiting varied treatment responses and prognoses.
• Systemic inflammation, indicated by neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), is linked to poorer outcomes in many cancers.
• Evaluating NLR and PLR in distinct breast cancer subtypes is crucial for understanding their prognostic significance.

Purpose of the Study:

• To investigate the association between NLR and PLR and different subtypes of breast cancer.
• To determine if inflammation markers differ significantly across luminal, HER2-positive, and triple-negative breast cancer subtypes.
• To assess the potential of NLR and PLR as indicators of inflammation within specific breast cancer classifications.

Main Methods:

• Retrospective analysis of 255 breast cancer patients.
• Classification of patients into luminal, HER2-positive, and triple-negative subtypes based on receptor status (ER, PR, HER2).
• Calculation of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for each patient.

Main Results:

• No significant differences in NLR were observed among the luminal, HER2-positive, and triple-negative breast cancer subtypes (p=0.051).
• PLR also showed no significant variation across the different breast cancer subtypes.
• A higher PLR was found in patients with lymph node metastasis compared to those without (p=0.03).

Conclusions:

• This study did not find significant differences in NLR and PLR values across the major breast cancer subtypes.
• While PLR showed a correlation with lymph node metastasis, NLR and PLR did not emerge as distinguishing markers for breast cancer subtypes in this cohort.
• Further research may be needed to elucidate the role of inflammation markers in specific breast cancer contexts.